Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus
- PMID: 1348843
Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus
Abstract
In 1989, the United States Public Health Service convened a Task Force of experts to consider the expanding knowledge base about prevention of Pneumocystis carinii pneumonia (PCP) among adults and adolescents (greater than or equal to 13 years of age) with human immunodeficiency virus (HIV) infection. This Task Force concluded that the morbidity, mortality, and cost due to PCP could be substantially reduced by appropriate use of antipneumocystis prophylaxis in subgroups of HIV-infected patients known to be at high risk, and developed recommendations for the administration of prophylactic regimens (1). The recommendations state that CD4+ T-lymphocyte counts should be monitored prospectively at 3- to 6-month intervals and prophylaxis should be instituted when patients become immunologically susceptible to PCP. Susceptibility was defined by a CD4+ T-lymphocyte count less than 200 cells/microliters or less than 20% of total circulating lymphocytes, or the occurrence of a previous episode of PCP. The goal of this approach was to reduce the frequency both of initial episodes of PCP (primary prophylaxis) and of relapses or recurrences (secondary prophylaxis). Either oral trimethoprim-sulfamethoxazole (TMP-SMX) or aerosol pentamidine was recommended for prophylaxis, but because direct comparative data were lacking, neither regimen was endorsed as "preferred." Since the recommendations were issued in 1989, additional information has become available about the efficacy and safety of aerosol pentamidine and oral TMP-SMX. A trial sponsored by the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group compared these two regimens in a prospective randomized study; in August 1991, this study was terminated by an independent data and safety monitoring board because statistically significantly fewer recurrences of PCP were observed in the oral TMP-SMX group than in the aerosol pentamidine group (2). On the basis of this finding and other studies assessing PCP prophylaxis, the Task Force was reconvened on October 5, 1991. This report contains the revised recommendations issued by the Task Force.
Similar articles
-
Trimethoprim-sulfamethoxazole versus aerosolized pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia: a prospective, randomized, controlled clinical trial. LFPMI Study Group. Ligue Française de Prévention des Maladies Infectieuses.J Acquir Immune Defic Syndr (1988). 1994 May;7(5):457-62. J Acquir Immune Defic Syndr (1988). 1994. PMID: 8158539 Clinical Trial.
-
From the Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV.JAMA. 1992 May 6;267(17):2294-6, 2298-9. JAMA. 1992. PMID: 1348788 No abstract available.
-
Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus.MMWR Recomm Rep. 1991 Mar 15;40(RR-2):1-13. MMWR Recomm Rep. 1991. PMID: 1672036
-
Prophylaxis for Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus.Clin Infect Dis. 1992 May;14(5):1005-9. doi: 10.1093/clinids/14.5.1005. Clin Infect Dis. 1992. PMID: 1350925 Review.
-
Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection.J Acquir Immune Defic Syndr (1988). 1993 Jan;6(1):46-55. J Acquir Immune Defic Syndr (1988). 1993. PMID: 8417174 Review. No abstract available.
Cited by
-
Analysis of a population-based Pneumocystis carinii pneumonia index as an outcome measure of access and quality of care for the treatment of HIV disease.Am J Public Health. 2002 Mar;92(3):395-8. doi: 10.2105/ajph.92.3.395. Am J Public Health. 2002. PMID: 11867318 Free PMC article.
-
Drug evaluation of concurrent Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium complex infections in a rat model.Antimicrob Agents Chemother. 1998 May;42(5):1068-72. doi: 10.1128/AAC.42.5.1068. Antimicrob Agents Chemother. 1998. PMID: 9593128 Free PMC article.
-
Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.Int J Epidemiol. 2002 Oct;31(5):951-8. doi: 10.1093/ije/31.5.951. Int J Epidemiol. 2002. PMID: 12435766 Free PMC article.
-
Primary care for patients infected with human immunodeficiency virus: a randomized controlled trial.J Gen Intern Med. 2001 Sep;16(9):573-82. doi: 10.1046/j.1525-1497.2001.016009573.x. J Gen Intern Med. 2001. PMID: 11556937 Free PMC article. Clinical Trial.
-
Treatment of Pneumocystis jirovecii pneumonia in non-human immunodeficiency virus-infected patients using a combination of trimethoprim-sulfamethoxazole and caspofungin.World J Clin Cases. 2022 Mar 26;10(9):2743-2750. doi: 10.12998/wjcc.v10.i9.2743. World J Clin Cases. 2022. PMID: 35434110 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials